8. REFERENCES
1.World Health Organization. Website. Access date January 2023.
https://www.who.int/health-topics/palliative-care
2.Paterson, C., et al. What are the unmet supportive care needs of men affected by penile cancer? A systematic review of the empirical evidence. Eur J Oncol Nurs, 2020. 48: 101805.
https://pubmed.ncbi.nlm.nih.gov/32947156/
3.Sakalis, V.I., et al. What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. Eur Urol Open Sci, 2022. 40: 58.
https://pubmed.ncbi.nlm.nih.gov/35540709/
4.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.
https://pubmed.ncbi.nlm.nih.gov/18436948/
5.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
https://pubmed.ncbi.nlm.nih.gov/18456631/
6.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009, updated 1998. Access date January 2023.
7.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413/
8.IARC, Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edn. Vol. 8. 2022.
9.Sanchez, D.F., et al. Pathological factors, behavior, and histological prognostic risk groups in subtypes of penile squamous cell carcinomas (SCC). Semin Diagn Pathol, 2015. 32: 222.
https://pubmed.ncbi.nlm.nih.gov/25677263/
10.Thomas, A., et al. Penile cancer. Nat Rev Dis Primers, 2021. 7: 11.
https://pubmed.ncbi.nlm.nih.gov/33574340/
11.Fu, L., et al. Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study. JMIR Public Health Surveill, 2022. 8: e34874.
https://pubmed.ncbi.nlm.nih.gov/35793140/
12.IARC, Cancer Today. 2020. Access date January 2023.
https://gco.iarc.fr/today/home
13.Parkin, D.M., et al. Chapter 2: The burden of HPV-related cancers. Vaccine, 2006. 24 Suppl 3: S3/11.
https://pubmed.ncbi.nlm.nih.gov/16949997/
14.Hansen, B.T., et al. Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015. Int J Cancer, 2018. 142: 1586.
https://pubmed.ncbi.nlm.nih.gov/29205336/
15.Cancer Research UK. Penile Cancer incidence trends over time. 2021. Access date January 2023.
16.Daubisse-Marliac, L., et al. Long-term trends in incidence and survival of penile cancer in France. Cancer Epidemiol, 2017. 50: 125.
https://pubmed.ncbi.nlm.nih.gov/28898817/
17.Backes, D.M., et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control, 2009. 20: 449.
https://pubmed.ncbi.nlm.nih.gov/19082746/
18.Qi, F., et al. Incidence trends and survival outcomes of penile squamous cell carcinoma: evidence from the Surveillance, Epidemiology and End Results population-based data. Ann Transl Med, 2020. 8: 1428.
https://pubmed.ncbi.nlm.nih.gov/33313173/
19.Wenzel, M., et al. Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. Cancer Causes Control, 2022. 33: 25.
https://pubmed.ncbi.nlm.nih.gov/34476653/
20.Chaux, A., et al. Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol, 2013. 31: 861.
https://pubmed.ncbi.nlm.nih.gov/22116602/
21.Barnholtz-Sloan, J.S., et al. Incidence trends in primary malignant penile cancer. Urol Oncol, 2007. 25: 361.
https://pubmed.ncbi.nlm.nih.gov/17826651/
22.Hartwig, S., et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer, 2012. 12: 30.
https://pubmed.ncbi.nlm.nih.gov/22260541/
23.Olesen, T.B., et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol, 2019. 20: 145.
https://pubmed.ncbi.nlm.nih.gov/30573285/
24.Xu, L., et al. Projected oropharyngeal carcinoma incidence among middle-aged US men. Head Neck, 2019. 41: 3226.
https://pubmed.ncbi.nlm.nih.gov/31125167/
25.IARC, 26-Penis Fact Sheet. 2020. Access date January 2023.
https://gco.iarc.fr/today/data/factsheets/cancers/26-Penis-fact-sheet.pdf
26.Douglawi, A., et al. Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol, 2017. 6: 785.
https://pubmed.ncbi.nlm.nih.gov/29184774/
27.Deng, X., et al. Trends in Incidence, Mortality, and Survival of Penile Cancer in the United States:
A Population-Based Study. Front Oncol, 2022. 12: 891623.
https://pubmed.ncbi.nlm.nih.gov/35785206/
28.Lebelo, R.L., et al. Diversity of HPV types in cancerous and pre-cancerous penile lesions of South African men: implications for future HPV vaccination strategies. J Med Virol, 2014. 86: 257.
https://pubmed.ncbi.nlm.nih.gov/24155172/
29.Stankiewicz, E., et al. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol, 2009. 22: 1160.
https://pubmed.ncbi.nlm.nih.gov/19465901/
30.Kayes, O., et al. Molecular and genetic pathways in penile cancer. Lancet Oncol, 2007. 8: 420.
https://pubmed.ncbi.nlm.nih.gov/17466899/
31.Nordenvall, C., et al. Cancer risk among patients with condylomata acuminata. Int J Cancer, 2006. 119: 888.
https://pubmed.ncbi.nlm.nih.gov/16557590/
32.Lont, A.P., et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer, 2006. 119: 1078.
https://pubmed.ncbi.nlm.nih.gov/16570278/
33.Bezerra, A.L., et al. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer, 2001. 91: 2315.
https://pubmed.ncbi.nlm.nih.gov/11413520/
34.Bandini, M., et al. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. Eur Urol Oncol, 2021. 4: 802.
https://www.sciencedirect.com/science/article/abs/pii/S2588931120301760?via%3Dihub
35.Hölters, S., et al. Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma. Virchows Arch, 2019. 475: 211.
https://pubmed.ncbi.nlm.nih.gov/30972551/
36.Sand, F.L., et al. Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev, 2018. 27: 1123.
https://pubmed.ncbi.nlm.nih.gov/29987099/
37.Liu, H., et al. Human papillomavirus as a favorable prognostic factor in a subset of head and neck squamous cell carcinomas: A meta-analysis. J Med Virol, 2017. 89: 710.
https://pubmed.ncbi.nlm.nih.gov/27575972/
38.Urbute, A., et al. Prognostic Significance of HPV DNA and p16(INK4a) in Anal Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev, 2020. 29: 703.
https://pubmed.ncbi.nlm.nih.gov/32051192/
39.Zhang, J., et al. Prognostic Significance of P16(INK4a) Expression in Penile Squamous Cell Carcinoma: A Meta-Analysis with Trial Sequential Analysis. Biomed Res Int, 2018. 2018: 8345893.
https://pubmed.ncbi.nlm.nih.gov/30105253/
40.Sand, F.L., et al. The prognostic value of p16 and p53 expression for survival after vulvar cancer:
A systematic review and meta-analysis. Gynecol Oncol, 2019. 152: 208.
https://pubmed.ncbi.nlm.nih.gov/30415992/
41.Mirghani, H., et al. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. Oral Oncol, 2017. 67: 138.
https://pubmed.ncbi.nlm.nih.gov/28351568/
42.de Bruijn, R.E., et al. Patients with penile cancer and the risk of (pre)malignant cervical lesions in female partners: a retrospective cohort analysis. BJU Int, 2013. 112: 905.
https://pubmed.ncbi.nlm.nih.gov/23905914/
43.Zhang, J., et al. The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis. Public Health, 2021. 196: 165.
https://pubmed.ncbi.nlm.nih.gov/34229128/
44.Harder, T., et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med, 2018. 16: 110.
https://pubmed.ncbi.nlm.nih.gov/30016957/
45.Elst, L., et al. HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions? Semin Oncol Nurs, 2022. 38: 151284.
https://pubmed.ncbi.nlm.nih.gov/35577640/
46.Tsen, H.F., et al. Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control, 2001. 12: 267.
https://pubmed.ncbi.nlm.nih.gov/11405332/
47.Koifman, L., et al. Epidemiological aspects of penile cancer in Rio de Janeiro: evaluation of 230 cases. Int Braz J Urol, 2011. 37: 231.
https://pubmed.ncbi.nlm.nih.gov/21557840/
48.Van Howe, R.S., et al. The carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol, 2006. 20: 1046.
https://pubmed.ncbi.nlm.nih.gov/16987256/
49.Daling, J.R., et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer, 2005. 116: 606.
https://pubmed.ncbi.nlm.nih.gov/15825185/
50.Velazquez, E.F., et al. Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol, 2004. 12: 139.
https://pubmed.ncbi.nlm.nih.gov/15173919/
51.Velazquez, E.F., et al. Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis: frequent atypias and correlation with special carcinoma variants suggests a precancerous role. Am
J Surg Pathol, 2003. 27: 1448.
https://pubmed.ncbi.nlm.nih.gov/14576478/
52.Teichman, J.M., et al. Noninfectious penile lesions. Am Fam Physician, 2010. 81: 167.
https://pubmed.ncbi.nlm.nih.gov/20082512/
53.Renaud-Vilmer, C., et al. Analysis of alterations adjacent to invasive squamous cell carcinoma of the penis and their relationship with associated carcinoma. J Am Acad Dermatol, 2010. 62: 284.
https://pubmed.ncbi.nlm.nih.gov/20115951/
54.Moch, H., et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2022. 82: 458.
https://pubmed.ncbi.nlm.nih.gov/35853783/
55.Chaux, A., et al. Metastatic tumors to the penis: a report of 17 cases and review of the literature. Int J Surg Pathol, 2011. 19: 597.
https://pubmed.ncbi.nlm.nih.gov/20075023/
56.Ebel, J.J., et al. Whole-mount evaluation of penectomies for penile cancer: feasibility, cost and comparison to routine sectioning. Histopathology, 2013. 63: 64.
https://pubmed.ncbi.nlm.nih.gov/23738630/
57.Corbishley C., et al. Standards and datasets for reporting cancers Dataset for penile and distal urethral cancer histopathology reports. 2015. 2022.
58.Tang, V., et al. Should centralized histopathological review in penile cancer be the global standard? BJU Int, 2014. 114: 340.
https://pubmed.ncbi.nlm.nih.gov/24053106/
59.Vanthoor, J., et al. Making surgery safer by centralization of care: impact of case load in penile cancer. World J Urol, 2020. 38: 1385.
https://pubmed.ncbi.nlm.nih.gov/31292733/
60.Aumayr, K., et al. P16INK4A immunohistochemistry for detection of human papilloma virus-associated penile squamous cell carcinoma is superior to in-situ hybridization. Int J Immunopathol Pharmacol, 2013. 26: 611.
https://pubmed.ncbi.nlm.nih.gov/24067458/
61.Bezerra, S.M., et al. Human papillomavirus infection and immunohistochemical p16(INK4a) expression as predictors of outcome in penile squamous cell carcinomas. Hum Pathol, 2015. 46: 532.
https://pubmed.ncbi.nlm.nih.gov/25661481/
62.Mannweiler, S., et al. Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression. J Am Acad Dermatol, 2013. 69: 73.
https://pubmed.ncbi.nlm.nih.gov/23474228/
63.Corbishley M., et al. Carcinoma of the Penis and Distal Urethra Histopathology Reporting Guide 1st edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-05-7. 2017.
https://nla.gov.au/nla.obj-775927924/view
64.Guimarães, G.C., et al. Front pattern of invasion in squamous cell carcinoma of the penis: new prognostic factor for predicting risk of lymph node metastases. Urology, 2006. 68: 148.
https://pubmed.ncbi.nlm.nih.gov/16844455/
65.Sanchez, D.F., et al. What Is New in the Pathologic Staging of Penile Carcinoma in the 8th Edition of AJCC TNM Model: Rationale for Changes With Practical Stage-by-stage Category Diagnostic Considerations. Adv Anat Pathol, 2021. 28: 209.
https://pubmed.ncbi.nlm.nih.gov/34050061/
66.Sali, A.P., et al. Histopathological risk scoring system as a tool for predicting lymph nodal metastasis in penile squamous cell carcinoma. Pathology, 2019. 51: 696.
https://pubmed.ncbi.nlm.nih.gov/31635947/
67.Winters, B.R., et al. Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology, 2016. 96: 29.
https://pubmed.ncbi.nlm.nih.gov/27450944/
68.Feng, M.A., et al. Concordance of lymphovascular invasion diagnosed in penile carcinoma with and without the immunohistochemical markers ERG and CD31. Histol Histopathol, 2016. 31: 293.
https://pubmed.ncbi.nlm.nih.gov/26452171/
69.Dorofte, L., et al. Low level of interobserver concordance in assessing histological subtype and tumor grade in patients with penile cancer may impair patient care. Virchows Arch, 2022. 480: 879.
https://pubmed.ncbi.nlm.nih.gov/34889977/
70.Cubilla, A.L. The role of pathologic prognostic factors in squamous cell carcinoma of the penis. World J Urol, 2009. 27: 169.
https://pubmed.ncbi.nlm.nih.gov/18766352/
71.Zekan, D.S., et al. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol, 2021. 47: 943.
https://pubmed.ncbi.nlm.nih.gov/33650835/
72.Fankhauser, C.D., et al. Lymphovascular and perineural invasion are risk factors for inguinal lymph node metastases in men with T1G2 penile cancer. J Cancer Res Clin Oncol, 2022. 148: 2231.
https://pubmed.ncbi.nlm.nih.gov/35411405/
73.Brierley, J., et al., TNM Classification of Malignant Tumours, 8th Edn. 2016.
https://www.uicc.org/resources/tnm-classification-malignant-tumours-8th-edition
74.Li, Z., et al. Corpora Cavernos invasion vs. Corpus Spongiosum invasion in Penile Cancer: A systematic review and meta-analysis. J Cancer, 2021. 12: 1960.
https://pubmed.ncbi.nlm.nih.gov/33753994/
75.Sali, A.P., et al. A comparative study of AJCC and the modified staging system in pT2/pT3 penile squamous cell carcinoma1398042195-1398042195a validation on an external data set. Histopathology, 2022. 80: 566.
https://pubmed.ncbi.nlm.nih.gov/34586682/
76.Zhang, Z.L., et al. The importance of extranodal extension in penile cancer: a meta-analysis. BMC Cancer, 2015. 15: 815.
https://pubmed.ncbi.nlm.nih.gov/26510975/
77.Gunia, S., et al. Does the width of the surgical margin of safety or premalignant dermatoses at the negative surgical margin affect outcome in surgically treated penile cancer? J Clin Pathol, 2014.
67: 268.
https://pubmed.ncbi.nlm.nih.gov/24100380/
78.Wang, J.Y., et al. Prognostic significance of the degree of extranodal extension in patients with penile carcinoma. Asian J Androl, 2014. 16: 437.
https://pubmed.ncbi.nlm.nih.gov/24480925/
79.Chaux, A., et al. The prognostic index: a useful pathologic guide for prediction of nodal metastases and survival in penile squamous cell carcinoma. Am J Surg Pathol, 2009. 33: 1049.
https://pubmed.ncbi.nlm.nih.gov/19384188/
80.Zito Marino, F., et al. Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study. Infect Agent Cancer, 2021. 16: 22.
https://pubmed.ncbi.nlm.nih.gov/33789689/
81.Cubilla, A.L., et al. Value of p16(INK)⁴(a) in the pathology of invasive penile squamous cell carcinomas: A report of 202 cases. Am J Surg Pathol, 2011. 35: 253.
https://pubmed.ncbi.nlm.nih.gov/21263246/
82.Canete-Portillo, S., et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers V: Recommendations on the Use of Immunohistochemical and Molecular Biomarkers in Penile Cancer. Am J Surg Pathol, 2020. 44: e80.
https://pubmed.ncbi.nlm.nih.gov/32235153/
83.Amin, M.B., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017. 67: 93.
https://pubmed.ncbi.nlm.nih.gov/28094848/
84.Velazquez, E.F., et al. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol, 2008. 32: 974.
https://pubmed.ncbi.nlm.nih.gov/18460979/
85.Leijte, J.A., et al. Evaluation of current TNM classification of penile carcinoma. J Urol, 2008. 180: 933.
https://pubmed.ncbi.nlm.nih.gov/18635216/
86.Sun, M., et al. Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU Int, 2015. 116: 734.
https://pubmed.ncbi.nlm.nih.gov/24552303/
87.Li, Z.S., et al. Modification of N staging systems for penile cancer: a more precise prediction of prognosis. Br J Cancer, 2015. 113: 1746.
https://pubmed.ncbi.nlm.nih.gov/26695555/
88.Chipollini, J., et al. Patient presentation, differential diagnosis, and management of penile lesions. Can Urol Assoc J, 2019. 13: S2.
https://pubmed.ncbi.nlm.nih.gov/31237837/
89.Lont, A.P., et al. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int, 2003. 91: 493.
https://pubmed.ncbi.nlm.nih.gov/12656901/
90.Bertolotto, M., et al. Primary and secondary malignancies of the penis: ultrasound features. Abdom Imaging, 2005. 30: 108.
https://pubmed.ncbi.nlm.nih.gov/15759326/
91.Kayes, O., et al. The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol, 2007. 51: 1313.
https://pubmed.ncbi.nlm.nih.gov/17113213/
92.Hanchanale, V., et al. The accuracy of magnetic resonance imaging (MRI) in predicting the invasion of the tunica albuginea and the urethra during the primary staging of penile cancer. BJU Int, 2016. 117: 439.
https://pubmed.ncbi.nlm.nih.gov/25600638/
93.Krishna, S., et al. Diagnostic Accuracy of MRI in Local Staging (T Category) of Penile Cancer and the Value of Artificial Erection: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol, 2022. 219: 28.
https://pubmed.ncbi.nlm.nih.gov/35195435/
94.Bozzini, G., et al. Role of Penile Doppler US in the Preoperative Assessment of Penile Squamous Cell Carcinoma Patients: Results From a Large Prospective Multicenter European Study. Urology, 2016. 90: 131.
https://pubmed.ncbi.nlm.nih.gov/26776562/
95.Wood, H.M., et al. Anatomic considerations of the penis, lymphatic drainage, and biopsy of the sentinel node. Urol Clin North Am, 2010. 37: 327.
https://pubmed.ncbi.nlm.nih.gov/20674689/
96.Horenblas, S., et al. Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol, 1994. 151: 1239.
https://pubmed.ncbi.nlm.nih.gov/8158767/
97.Srinivas, V., et al. Penile cancer: relation of extent of nodal metastasis to survival. J Urol, 1987.
137: 880.
https://pubmed.ncbi.nlm.nih.gov/3573181/
98.Kroon, B.K., et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol, 2005. 173: 816.
https://pubmed.ncbi.nlm.nih.gov/15711276/
99.Horenblas, S., et al. Squamous cell carcinoma of the penis. II. Treatment of the primary tumor.
J Urol, 1992. 147: 1533.
https://pubmed.ncbi.nlm.nih.gov/1593683/
100.Woldu, S.L., et al. Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. Urol Oncol, 2018. 36: 159.e7.
https://pubmed.ncbi.nlm.nih.gov/29288008/
101.Mueller-Lisse, U.G., et al. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr Opin Urol, 2008. 18: 105.
https://pubmed.ncbi.nlm.nih.gov/18090498/
102.Leijte, J.A., et al. Prospective evaluation of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int, 2009. 104: 640.
https://pubmed.ncbi.nlm.nih.gov/19281465/
103.Schlenker, B., et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol, 2012. 30: 55.
https://pubmed.ncbi.nlm.nih.gov/20022269/
104.Jakobsen, J.K., et al. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer. BJU Int, 2021. 127: 254.
https://pubmed.ncbi.nlm.nih.gov/33448605/
105.Sadeghi, R., et al. Accuracy of 18F-FDG PET/CT for diagnosing inguinal lymph node involvement in penile squamous cell carcinoma: systematic review and meta-analysis of the literature. Clin Nucl Med, 2012. 37: 436.
https://pubmed.ncbi.nlm.nih.gov/22475891/
106.Krishna, R.P., et al. Sonography: an underutilized diagnostic tool in the assessment of metastatic groin nodes. J Clin Ultrasound, 2008. 36: 212.
https://pubmed.ncbi.nlm.nih.gov/17960822/
107.Kroon, B.K., et al. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int, 2005. 95: 517.
https://pubmed.ncbi.nlm.nih.gov/15705071/
108.Lee, E.W.C., et al. High diagnostic accuracy of inguinal ultrasonography and fine-needle aspiration followed by dynamic sentinel lymph node biopsy in men with impalpable and palpable inguinal lymph nodes. BJU Int, 2022. 130: 331.
https://pubmed.ncbi.nlm.nih.gov/35098622/
109.Graafland, N.M., et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol, 2010. 58: 742.
https://pubmed.ncbi.nlm.nih.gov/20800339/
110.Catalona, W.J. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol, 1988. 140: 306.
https://pubmed.ncbi.nlm.nih.gov/3398125/
111.Protzel, C., et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol, 2009. 55: 1075.
https://pubmed.ncbi.nlm.nih.gov/19264390/
112.d’Ancona, C.A., et al. Long-term followup of penile carcinoma treated with penectomy and bilateral modified inguinal lymphadenectomy. J Urol, 2004. 172: 498.
https://pubmed.ncbi.nlm.nih.gov/15247713/
113.Thyavihally, Y.B., et al. Comparative study of perioperative and survival outcomes after video endoscopic inguinal lymphadenectomy (VEIL) and open inguinal lymph node dissection (O-ILND) in the management of inguinal lymph nodes in carcinoma of the penis. J Robot Surg, 2021. 15: 905.
https://pubmed.ncbi.nlm.nih.gov/33484414/
114.Wever, L., et al. Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer. BJU Int, 2022. 130: 486.
https://pubmed.ncbi.nlm.nih.gov/35257463/
115.Gopman, J.M., et al. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int, 2015. 116: 196.
https://pubmed.ncbi.nlm.nih.gov/25777366/
116.Gómez-Ferrer, A., et al. A single-center comparison of our initial experiences in treating penile and urethral cancer with video-endoscopic inguinal lymphadenectomy (VEIL) and later experiences in melanoma cases. Front Surg, 2022. 9: 870857.
https://pubmed.ncbi.nlm.nih.gov/36225221/
117.Muñoz Guillermo, V., et al. [Video endoscopic inguinal lymphadenectomy in penile cancer: Systematic review]. Arch Esp Urol, 2019. 72: 992.
https://pubmed.ncbi.nlm.nih.gov/31823847/
118.Horenblas, S., et al. Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol, 2000. 163: 100.
https://pubmed.ncbi.nlm.nih.gov/10604324/
119.de Vries, H.M., et al. Clinicopathological predictors of finding additional inguinal lymph node metastases in penile cancer patients after positive dynamic sentinel node biopsy: a European multicentre evaluation. BJU Int, 2022. 130: 126.
https://pubmed.ncbi.nlm.nih.gov/34927790/
120.Dell’Oglio, P., et al. Hybrid Indocyanine Green-(99m)Tc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution. Eur Urol, 2020. 78: 865.
https://pubmed.ncbi.nlm.nih.gov/32950298/
121.Leijte, J.A., et al. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol, 2007. 52: 170.
https://pubmed.ncbi.nlm.nih.gov/17316967/
122.Zou, Z.J., et al. Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and meta-analysis. Int Urol Nephrol, 2016. 48: 2001.
https://pubmed.ncbi.nlm.nih.gov/27577753/
123.Hughes, B., et al. Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer. World J Urol, 2009. 27: 197.
https://pubmed.ncbi.nlm.nih.gov/18594830/
124.Hövels, A.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol, 2008. 63: 387.
https://pubmed.ncbi.nlm.nih.gov/18325358/
125.Antoch, G., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol, 2004. 22: 4357.
https://pubmed.ncbi.nlm.nih.gov/15514377/
126.Graafland, N.M., et al. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol, 2009. 56: 339.
https://pubmed.ncbi.nlm.nih.gov/19477581/
127.Ashley, S., et al. Human Papilloma Virus (HPV) status may impact treatment outcomes in patients with pre-cancerous penile lesions (an eUROGEN Study). Int J Impot Res, 2021. 33: 620.
https://pubmed.ncbi.nlm.nih.gov/32710000/
128.Hoekstra, R.J., et al. Penile intraepithelial neoplasia: Nomenclature, incidence and progression to malignancy in the Netherlands. Int J Urol, 2019. 26: 353.
https://pubmed.ncbi.nlm.nih.gov/30508877/
129.Kravvas, G., et al. The management of penile intraepithelial neoplasia (PeIN): clinical and histological features and treatment of 345 patients and a review of the literature. J Dermatolog Treat, 2022.
33: 1047.
https://pubmed.ncbi.nlm.nih.gov/32705920/
130.Kristiansen, S., et al. Incidence of penile intraepithelial neoplasia and treatment strategies in Sweden 2000-2019. BJU Int, 2022. 129: 752.
https://pubmed.ncbi.nlm.nih.gov/35044047/
131.Alnajjar, H.M., et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol, 2012. 62: 923.
https://pubmed.ncbi.nlm.nih.gov/22421082/
132.Issa, A., et al. Treatment Options and Outcomes for Men with Penile Intraepithelial Neoplasia:
A Systematic Review. Eur Urol Focus, 2022. 8: 829.
https://pubmed.ncbi.nlm.nih.gov/33994168/
133.Kim, J.Y.S., et al. Guidelines of care for the management of cutaneous squamous cell carcinoma.
J Am Acad Dermatol, 2018. 78: 560.
https://pubmed.ncbi.nlm.nih.gov/29331386/
134.Leone, A., et al. Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors. Eur Urol, 2017. 72: 4.
https://pubmed.ncbi.nlm.nih.gov/28131464/
135.Shaw, K.S., et al. Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia. JAAD Case Rep, 2017. 3: 546.
https://pubmed.ncbi.nlm.nih.gov/29264388/
136.Paoli, J., et al. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol, 2006. 86: 418.
https://pubmed.ncbi.nlm.nih.gov/16955186/
137.Schlenker, B., et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int, 2010. 106: 786.
https://pubmed.ncbi.nlm.nih.gov/20089106/
138.Meijer, R.P., et al. Long-term follow-up after laser therapy for penile carcinoma. Urology, 2007.
69: 759.
https://pubmed.ncbi.nlm.nih.gov/17445665/
139.Shabbir, M., et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol, 2011. 59: 142.
https://pubmed.ncbi.nlm.nih.gov/21050658/
140.Caldamone, A.A., et al. Buccal mucosal grafts for urethral reconstruction. Urology, 1998. 51: 15.
https://pubmed.ncbi.nlm.nih.gov/9610551/
141.Håkansson, U., et al. Organ-sparing reconstructive surgery in penile cancer: initial experiences at two Swedish referral centres. Scand J Urol, 2015. 49: 149.
https://pubmed.ncbi.nlm.nih.gov/25313620/
142.Pang, K.H., et al. Advances in penile-sparing surgical approaches. Asian J Urol, 2022. 9: 359.
https://pubmed.ncbi.nlm.nih.gov/36381598/
143.Cakir, O.O., et al. Surgical technique and outcomes following coronal-sparing glans resurfacing for benign and malignant penile lesions. Int J Impot Res, 2022. 34: 495.
https://pubmed.ncbi.nlm.nih.gov/34285385/
144.Corbishley, C.M., et al. Glans resurfacing for precancerous and superficially invasive carcinomas of the glans penis: Pathological specimen handling and reporting. Semin Diagn Pathol, 2015. 32: 232.
https://pubmed.ncbi.nlm.nih.gov/25662797/
145.Roussel, E., et al. Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma? BJU Int, 2021. 127: 606.
https://pubmed.ncbi.nlm.nih.gov/33180969/
146.Djajadiningrat, R.S., et al. Penile sparing surgery for penile cancer-does it affect survival? J Urol, 2014. 192: 120.
https://pubmed.ncbi.nlm.nih.gov/24373799/
147.Leijte, J.A., et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol, 2008. 54: 161.
https://pubmed.ncbi.nlm.nih.gov/18440124/
148.Agrawal, A., et al. The histological extent of the local spread of carcinoma of the penis and its therapeutic implications. BJU Int, 2000. 85: 299.
https://pubmed.ncbi.nlm.nih.gov/10671885/
149.Minhas, S., et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int, 2005. 96: 1040.
https://pubmed.ncbi.nlm.nih.gov/16225525/
150.Philippou, P., et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol, 2012. 188: 803.
https://pubmed.ncbi.nlm.nih.gov/22818137/
151.Sri, D., et al. A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int, 2018. 122: 576.
https://pubmed.ncbi.nlm.nih.gov/29604228/
152.Ellul, T., et al. Frozen section analysis for organ-conserving surgery in penile cancer: Assessing oncological outcomes and trends of local recurrence. J Clin Urol, 2020. 13: 419.
https://journals.sagepub.com/doi/full/10.1177/2051415820903192
153.Kamel, M.H., et al. Organ Sparing Surgery for Penile Cancer: A Systematic Review. J Urol, 2017. 198: 770.
https://pubmed.ncbi.nlm.nih.gov/28286072/
154.Tang, D.H., et al. Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urol Oncol, 2018. 36: 147.
https://pubmed.ncbi.nlm.nih.gov/29097087/
155.Musi, G., et al. Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. World J Urol, 2018. 36: 265.
https://pubmed.ncbi.nlm.nih.gov/29197968/
156.Falcone, M., et al. Total Glans Resurfacing for the Management of Superficial Penile Cancer: A Retrospective Cohort Analysis in a Tertiary Referral Center. Urology, 2020. 145: 281.
https://pubmed.ncbi.nlm.nih.gov/32683069/
157.Pérez, J., et al. Oncological and Functional Outcomes After Organ-Sparing Plastic Reconstructive Surgery for Penile Cancer. Urology, 2020. 142: 161.
https://pubmed.ncbi.nlm.nih.gov/32380155/
158.O’Kelly, F., et al. A Prospective Study of Total Glans Resurfacing for Localized Penile Cancer to Maximize Oncologic and Functional Outcomes in a Tertiary Referral Network. J Urol, 2017. 197: 1258.
https://pubmed.ncbi.nlm.nih.gov/28027867/
159.Pang, K.H., et al. Glansectomy and Reconstruction for Penile Cancer: A Systematic Review. Eur Urol Focus, 2021.
https://pubmed.ncbi.nlm.nih.gov/34903488/
160.Crook, J., et al. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy, 2010. 9: 151.
https://pubmed.ncbi.nlm.nih.gov/19854685/
161.de Crevoisier, R., et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys, 2009. 74: 1150.
https://pubmed.ncbi.nlm.nih.gov/19395183/
162.Delaunay, B., et al. Brachytherapy for penile cancer: efficacy and impact on sexual function. Brachytherapy, 2014. 13: 380.
https://pubmed.ncbi.nlm.nih.gov/23896397/
163.Kamsu-Kom, L., et al. Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol), 2015. 27: 387.
https://pubmed.ncbi.nlm.nih.gov/26003455/
164.Sharma, D.N., et al. High-dose-rate interstitial brachytherapy for T1-T2-stage penile carcinoma: short-term results. Brachytherapy, 2014. 13: 481.
https://pubmed.ncbi.nlm.nih.gov/25037912/
165.Pohanková, D., et al. High-Dose Rate Brachytherapy in the Treatment of Early Stages of Penile Carcinoma. Klin Onkol, 2019. 32: 52.
https://pubmed.ncbi.nlm.nih.gov/30764630/
166.Martz, N., et al. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis. Clin Transl Radiat Oncol, 2021. 27: 89.
https://pubmed.ncbi.nlm.nih.gov/33537466/
167.Kellas-Ślęczka, S., et al. Nineteen-year single-center experience in 76 patients with penile cancer treated with high-dose-rate brachytherapy. Brachytherapy, 2019. 18: 493.
https://pubmed.ncbi.nlm.nih.gov/31101437/
168.Rouscoff, Y., et al. High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis. Radiat Oncol, 2014. 9: 142.
https://pubmed.ncbi.nlm.nih.gov/24941956/
169.Rishi, A., et al. Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer. Brachytherapy, 2022. 21: 839.
https://pubmed.ncbi.nlm.nih.gov/35915039/
170.Azrif, M., et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol), 2006. 18: 320.
https://pubmed.ncbi.nlm.nih.gov/16703750/
171.Rozan, R., et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol, 1995. 36: 83.
https://pubmed.ncbi.nlm.nih.gov/7501816/
172.Delannes, M., et al. Iridium-192 interstitial therapy for squamous cell carcinoma of the penis. Int
J Radiat Oncol Biol Phys, 1992. 24: 479.
https://pubmed.ncbi.nlm.nih.gov/1399733/
173.Hasan, S., et al. The role of brachytherapy in organ preservation for penile cancer: A meta-analysis and review of the literature. Brachytherapy, 2015. 14: 517.
https://pubmed.ncbi.nlm.nih.gov/25944394/
174.Zouhair, A., et al. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer, 2001. 37: 198.
https://pubmed.ncbi.nlm.nih.gov/11166146/
175.Cordoba, A., et al. Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients). Radiat Oncol, 2016. 11: 96.
https://pubmed.ncbi.nlm.nih.gov/27464910/
176.Gambachidze, D., et al. Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. Brachytherapy, 2018. 17: 221.
https://pubmed.ncbi.nlm.nih.gov/29089276/
177.Djajadiningrat, R.S., et al. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer, 2015. 13: 44.
https://pubmed.ncbi.nlm.nih.gov/25009098/
178.Johnstone, P.A.S., et al. Changing Radiotherapy Paradigms in Penile Cancer. Eur Urol Open Sci, 2022. 36: 47.
https://pubmed.ncbi.nlm.nih.gov/35028598/
179.Ottenhof, S.R., et al. Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus, 2019. 5: 867.
https://pubmed.ncbi.nlm.nih.gov/29433986/
180.Pagliaro, L.C., et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol, 2010. 28: 3851.
https://pubmed.ncbi.nlm.nih.gov/20625118/
181.Pizzocaro, G., et al. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol, 2009. 55: 546.
https://pubmed.ncbi.nlm.nih.gov/18649992/
182.Necchi, A., et al. Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clin Genitourin Cancer, 2017. 15: 548.
https://pubmed.ncbi.nlm.nih.gov/28325636/
183.Nicolai, N., et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clin Genitourin Cancer, 2016. 14: 323.
https://pubmed.ncbi.nlm.nih.gov/26341040/
184.Nicholson, S., et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer, 2013. 109: 2554.
https://pubmed.ncbi.nlm.nih.gov/24169355/
185.Nicholson, S., et al. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. Br J Cancer, 2022. 126: 34.
https://pubmed.ncbi.nlm.nih.gov/34671131/
186.Theodore, C., et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol, 2008. 19: 1304.
https://pubmed.ncbi.nlm.nih.gov/18417462/
187.Azizi, M., et al. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? J Urol, 2020.
203: 1147.
https://pubmed.ncbi.nlm.nih.gov/31928407/
188.Yi, X.Y., et al. Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence. Asian J Androl, 2022. 24: 180.
https://pubmed.ncbi.nlm.nih.gov/34975068/
189.McComas, K., et al. Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer, 2020. 18: e573.
https://pubmed.ncbi.nlm.nih.gov/32335061/
190.Ottenhof, S.R., et al. 497 - Chemoradiation in the treatment of loco-regionally advanced penile cancer. Eur Urol Suppl, 2019. 18: e655.
https://www.sciencedirect.com/science/article/abs/pii/S1569905619304841?via%3Dihub
191.Ornellas, A.A., et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol, 2008. 97: 487.
https://pubmed.ncbi.nlm.nih.gov/18425779/
192.Veeratterapillay, R., et al. Oncologic Outcomes of Penile Cancer Treatment at a UK Supraregional Center. Urology, 2015. 85: 1097.
https://pubmed.ncbi.nlm.nih.gov/25769781/
193.Gotsadze, D., et al. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol, 2000. 38: 306.
https://pubmed.ncbi.nlm.nih.gov/10940705/
194.Daseler, E.H., et al. Radical excision of the inguinal and iliac lymph glands; a study based upon 450 anatomical dissections and upon supportive clinical observations. Surg Gynecol Obstet, 1948.
87: 679.
https://pubmed.ncbi.nlm.nih.gov/18120502/
195.Leijte, J.A., et al. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol, 2008. 54: 885.
https://pubmed.ncbi.nlm.nih.gov/18502024/
196.Omorphos, S., et al. Zonal mapping of sentinel lymph nodes in penile cancer patients using fused SPECT/CT imaging and lymphoscintigraphy. Urol Oncol, 2018. 36: 530.e1.
https://pubmed.ncbi.nlm.nih.gov/30318180/
197.Yao, K., et al. Lymph Node Mapping in Patients with Penile Cancer Undergoing Pelvic Lymph Node Dissection. J Urol, 2021. 205: 145.
https://pubmed.ncbi.nlm.nih.gov/32755338/
198.Culkin, D.J., et al. Advanced penile carcinoma. J Urol, 2003. 170: 359.
https://pubmed.ncbi.nlm.nih.gov/12853775/
199.Leewansangtong, S., et al. The risks of lymph node metastasis and the prognostic factors in carcinoma of the penis: analysis of 50 patients treated with bilateral ilioinguinal lymphadenectomy.
J Med Assoc Thai, 2001. 84: 204.
https://pubmed.ncbi.nlm.nih.gov/11336079/
200.Marconnet, L., et al. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol, 2010. 183: 2227.
https://pubmed.ncbi.nlm.nih.gov/20399455/
201.Martin, T.G., et al. Inguinal Lymphadenectomy for Squamous Cell Cancer of the Penis—Experience of a UK Supra-Regional Network. Brit J Med Surg Urol, 2012. 5: 241.
https://journals.sagepub.com/doi/10.1016/j.bjmsu.2011.12.009
202.Joshi, S.S., et al. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol, 2018. 4: 643.
https://pubmed.ncbi.nlm.nih.gov/29494739/
203.Johnson, T.V., et al. Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program. Cancer, 2010. 116: 2960.
https://pubmed.ncbi.nlm.nih.gov/20564401/
204.Chang, E.K., et al. Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer. Urol Pract, 2021. 8: 348.
https://pubmed.ncbi.nlm.nih.gov/33898656/
205.Cindolo, L., et al. Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World J Urol, 2019. 37: 1649.
https://pubmed.ncbi.nlm.nih.gov/30377813/
206.Fankhauser, C.D., et al. Practice Patterns Among Penile Cancer Surgeons Performing Dynamic Sentinel Lymph Node Biopsy and Radical Inguinal Lymph Node Dissection in Men with Penile Cancer: A eUROGEN Survey. Eur Urol Open Sci, 2021. 24: 39.
https://pubmed.ncbi.nlm.nih.gov/34337494/
207.Yao, K., et al. Fascia lata preservation during inguinal lymphadenectomy for penile cancer: rationale and outcome. Urology, 2013. 82: 642.
https://pubmed.ncbi.nlm.nih.gov/23876593/
208.Chipollini, J., et al. Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU Int, 2020. 125: 82.
https://pubmed.ncbi.nlm.nih.gov/31356716/
209.Li, Z.S., et al. Disease-specific survival after radical lymphadenectomy for penile cancer: prediction by lymph node count and density. Urol Oncol, 2014. 32: 893.
https://pubmed.ncbi.nlm.nih.gov/24994488/
210.Mao, W., et al. More lymph node dissection improves survival in patients with newly diagnosed lymph node-positive penile cancer. Int Urol Nephrol, 2019. 51: 641.
https://pubmed.ncbi.nlm.nih.gov/30758771/
211.Soodana-Prakash, N., et al. Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer. Urol Oncol, 2018. 36: 471.e19.
https://pubmed.ncbi.nlm.nih.gov/30143385/
212.Zhu, Y., et al. Population-based assessment of the number of lymph nodes removed in the treatment of penile squamous cell carcinoma. Urol Int, 2014. 92: 186.
https://pubmed.ncbi.nlm.nih.gov/24246932/
213.Johnson, D.E., et al. Management of regional lymph nodes in penile carcinoma. Five-year results following therapeutic groin dissections. Urology, 1984. 24: 308.
https://pubmed.ncbi.nlm.nih.gov/6485188/
214.Chipollini, J., et al. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol, 2017. 198: 1346.
https://pubmed.ncbi.nlm.nih.gov/28652123/
215.Gulia, A.K., et al. Impact of delay in inguinal lymph node dissection in patients with carcinoma of penis. Indian J Cancer, 2009. 46: 214.
https://pubmed.ncbi.nlm.nih.gov/19574673/
216.Hegarty, P.K., et al. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am, 2010. 37: 421.
https://pubmed.ncbi.nlm.nih.gov/20674697/
217.Ravi, R. Morbidity following groin dissection for penile carcinoma. Br J Urol, 1993. 72: 941.
https://pubmed.ncbi.nlm.nih.gov/8306161/
218.Koifman, L., et al. Radical open inguinal lymphadenectomy for penile carcinoma: surgical technique, early complications and late outcomes. J Urol, 2013. 190: 2086.
https://pubmed.ncbi.nlm.nih.gov/23770135/
219.Stuiver, M.M., et al. Early wound complications after inguinal lymphadenectomy in penile cancer: a historical cohort study and risk-factor analysis. Eur Urol, 2013. 64: 486.
https://pubmed.ncbi.nlm.nih.gov/23490726/
220.Sharma, P., et al. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol, 2015. 33: 1585.
https://pubmed.ncbi.nlm.nih.gov/25552207/
221.Bevan-Thomas, R., et al. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol, 2002. 167: 1638.
https://pubmed.ncbi.nlm.nih.gov/11912379/
222.Bouchot, O., et al. Morbidity of inguinal lymphadenectomy for invasive penile carcinoma. Eur Urol, 2004. 45: 761.
https://pubmed.ncbi.nlm.nih.gov/15149749/
223.Mistretta, F.A., et al. Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. Urol Oncol, 2019. 37: 578.e11.
https://pubmed.ncbi.nlm.nih.gov/31296420/
224.Nelson, B.A., et al. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol, 2004. 172: 494.
https://pubmed.ncbi.nlm.nih.gov/15247712/
225.Ray, M.D., et al. Minimizing Post-operative Complications of Groin Dissection Using Modified Skin Bridge Technique: A Single-Centre Descriptive Study Showing Post-operative and Early Oncological Outcomes. World J Surg, 2018. 42: 3196.
https://pubmed.ncbi.nlm.nih.gov/29654358/
226.Bertheuil, N., et al. Inguinal lymphadenectomy for stage III melanoma: a comparative study of two surgical approaches at the onset of lymphoedema. Eur J Surg Oncol, 2015. 41: 215.
https://pubmed.ncbi.nlm.nih.gov/25524886/
227.Abbas, S., et al. Systematic review and meta-analysis of the used surgical techniques to reduce leg lymphedema following radical inguinal nodes dissection. Surg Oncol, 2011. 20: 88.
https://pubmed.ncbi.nlm.nih.gov/20005090/
228.Tonouchi, H., et al. Operative morbidity associated with groin dissections. Surg Today, 2004. 34: 413.
https://pubmed.ncbi.nlm.nih.gov/15108079/
229.Schmid, S.C., et al. Final results of the PräVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure. World J Urol, 2021. 39: 613.
https://pubmed.ncbi.nlm.nih.gov/32372159/
230.Tranoulis, A., et al. The Impact of Saphenous Vein Sparing During Inguinal Lymphadenectomy on Postoperative Morbidity in Women With Vulval Cancer: An Updated Per-Groin Meta-analysis of Short-term Outcomes. Int J Gynecol Cancer, 2018. 28: 1232.
https://pubmed.ncbi.nlm.nih.gov/29787421/
231.Cui, Y., et al. Saphenous vein sparing during laparoscopic bilateral inguinal lymphadenectomy for penile carcinoma patients. Int Urol Nephrol, 2016. 48: 363.
https://pubmed.ncbi.nlm.nih.gov/26660956/
232.Pouwer, A.W., et al. Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study. Gynecol Oncol, 2017. 146: 580.
https://pubmed.ncbi.nlm.nih.gov/28687171/
233.Weldrick, C., et al. A comparison of fibrin sealant versus standard closure in the reduction of postoperative morbidity after groin dissection: A systematic review and meta-analysis. Eur J Surg Oncol, 2014. 40: 1391.
https://pubmed.ncbi.nlm.nih.gov/25125341/
234.Matthey-Gié, M.L., et al. Prospective Randomized Study to Compare Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Therapeutic Lymph Node Dissection With or Without the Use of an Ultrasonic Scalpel. Ann Surg Oncol, 2016. 23: 1716.
https://pubmed.ncbi.nlm.nih.gov/26714939/
235.Pouwer, A.W., et al. Reduced morbidity by using LigaSure compared to conventional inguinofemoral lymphadenectomy in vulvar cancer patients: A randomized controlled trial. Surg Oncol, 2020. 35: 149.
https://pubmed.ncbi.nlm.nih.gov/32877884/
236.Schwentner, C., et al. Endoscopic inguinofemoral lymphadenectomy--extended follow-up.
J Endourol, 2013. 27: 497.
https://pubmed.ncbi.nlm.nih.gov/23067251/
237.Kumar, V., et al. Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period. BJU Int, 2017. 119: 530.
https://pubmed.ncbi.nlm.nih.gov/27628265/
238.Singh, A., et al. Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis. J Urol, 2018. 199: 1518.
https://pubmed.ncbi.nlm.nih.gov/29307685/
239.Mosti, G., et al. Compression therapy in lymphedema: Between past and recent scientific data. Phlebology, 2019. 34: 515.
https://pubmed.ncbi.nlm.nih.gov/30626269/
240.Ettema, H.B., et al. Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials. J Thromb Haemost, 2008. 6: 1093.
https://pubmed.ncbi.nlm.nih.gov/18429944/
241.Lightner, D.J., et al. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol, 2020. 203: 351.
https://pubmed.ncbi.nlm.nih.gov/31441676/
242.Jindal, T., et al. Laparoscopic and robotic video endoscopic inguinal lymphadenectomy by the lateral approach. Asian J Endosc Surg, 2021. 14: 464.
https://pubmed.ncbi.nlm.nih.gov/33200462/
243.Yuan, P., et al. Comparative Study of Video Endoscopic Inguinal Lymphadenectomy Through a Hypogastric vs Leg Subcutaneous Approach for Penile Cancer. J Endourol, 2018. 32: 66.
https://pubmed.ncbi.nlm.nih.gov/29256632/
244.Subirá-Ríos, D., et al. Minimally Invasive Laparoscopic Technique for Lymph Node Dissection in Penile Cancer: The Pelvic and Inguinal Single-Site Approach: PISA Technique. Urology, 2021. 153: 351.
https://pubmed.ncbi.nlm.nih.gov/33915082/
245.Postlewait, L.M., et al. A Minimally Invasive Approach for Inguinal Lymphadenectomy in Melanoma and Genitourinary Malignancy: Long-Term Outcomes in an Attempted Randomized Control Trial. Ann Surg Oncol, 2017. 24: 3237.
https://pubmed.ncbi.nlm.nih.gov/28770482/
246.Fankhauser, C.D., et al. Saphenous-sparing Ascending Video Endoscopic Inguinal Lymph Node Dissection Using a Leg Approach: Surgical Technique and Perioperative and Pathological Outcomes. Eur Urol Open Sci, 2022. 35: 9.
https://pubmed.ncbi.nlm.nih.gov/34825230/
247.Wang, S., et al. Comparison of Efficiency of Video Endoscopy and Open Inguinal Lymph Node Dissection. Anticancer Res, 2017. 37: 4623.
https://pubmed.ncbi.nlm.nih.gov/28739762/
248.Shao, Y., et al. Comparison of different surgical methods and strategies for inguinal lymph node dissection in patients with penile cancer. Sci Rep, 2022. 12: 2560.
https://pubmed.ncbi.nlm.nih.gov/35169241/
249.Lont, A.P., et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol, 2007. 177: 947.
https://pubmed.ncbi.nlm.nih.gov/17296384/
250.Liu, J.Y., et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol, 2013. 31: 1519.
https://pubmed.ncbi.nlm.nih.gov/23455885/
251.Djajadiningrat, R.S., et al. Prophylactic pelvic lymph node dissection in patients with penile cancer.
J Urol, 2015. 193: 1976.
https://pubmed.ncbi.nlm.nih.gov/25498573/
252.Lughezzani, G., et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J Urol, 2014. 191: 977.
https://pubmed.ncbi.nlm.nih.gov/24262497/
253.Zhu, Y., et al. Prospectively packaged ilioinguinal lymphadenectomy for penile cancer: the disseminative pattern of lymph node metastasis. J Urol, 2009. 181: 2103.
https://pubmed.ncbi.nlm.nih.gov/19286211/
254.Li, Z.S., et al. Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. J Cancer Res Clin Oncol, 2017. 143: 329.
https://pubmed.ncbi.nlm.nih.gov/27771796/
255.Ottenhof, S.R., et al. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma. Eur Urol Focus, 2022. 8: 98.
https://pubmed.ncbi.nlm.nih.gov/33685842/
256.Sachdeva A., et al. Management of lymph node-positive penile cancer: a systematic review. prior to print.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=290784
257.Ravi, R., et al. Role of radiation therapy in the treatment of carcinoma of the penis. Br J Urol, 1994. 74: 646.
https://pubmed.ncbi.nlm.nih.gov/7530129/
258.Alnajjar, H.M., et al. Long-term outcomes for penile cancer patients presenting with advanced N3 disease requiring a myocutaneous flap reconstruction or primary closure-a retrospective single centre study. Transl Androl Urol, 2019. 8: S13.
https://pubmed.ncbi.nlm.nih.gov/31143667/
259.Koifman, L., et al. The role of primary inguinal surgical debulking for locally advanced penile cancer followed by reconstruction with myocutaneous flap. Int Braz J Urol, 2021. 47: 1162.
https://pubmed.ncbi.nlm.nih.gov/34115458/
260.Canter, D.J., et al. The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status. Eur Urol Focus, 2019. 5: 706.
https://pubmed.ncbi.nlm.nih.gov/31160252/
261.Hussein, A.M., et al. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer, 1990. 65: 433.
https://pubmed.ncbi.nlm.nih.gov/2297633/
262.Shammas, F.V., et al. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol, 1992.
147: 630.
https://pubmed.ncbi.nlm.nih.gov/1538445/
263.Leijte, J.A., et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol, 2007. 52: 488.
https://pubmed.ncbi.nlm.nih.gov/17316964/
264.Sharma, P., et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol, 2015. 33: 496 e17.
https://pubmed.ncbi.nlm.nih.gov/26072110/
265.Necchi, A., et al. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. Clin Genitourin Cancer, 2016. 14: 518.
https://pubmed.ncbi.nlm.nih.gov/27050716/
266.Necchi, A., et al. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urol Oncol, 2019. 37: 531.e7.
https://pubmed.ncbi.nlm.nih.gov/31053524/
267.Raup, V., et al. MP49-09 - Adjuvant chemotherapy in the treatment of lymph node positive squamous cell carcinoma of the penis: analysis of the national cancer data base. J Urol, 2019.
201: e709.
https://www.auajournals.org/doi/10.1097/01.JU.0000556432.48421.1e
268.Paz Rojas, J.F., et al. Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis. Urol Oncol, 2022. 40: 200.e11.
https://pubmed.ncbi.nlm.nih.gov/35307290/
269.Patel, A., et al. Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer. Asian J Urol, 2022. 9: 389.
https://pubmed.ncbi.nlm.nih.gov/36381600/
270.Hakenberg, O.W., et al. EAU guidelines on penile cancer: 2014 update. Eur Urol, 2015. 67: 142.
https://pubmed.ncbi.nlm.nih.gov/25457021/
271.Robinson, R., et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. Eur Urol, 2018. 74: 76.
https://pubmed.ncbi.nlm.nih.gov/29703686/
272.Chen, M.F., et al. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol, 2004. 22: 60.
https://pubmed.ncbi.nlm.nih.gov/14657999/
273.Yuan, Z., et al. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World J Urol, 2018. 36: 1431.
https://pubmed.ncbi.nlm.nih.gov/29589134/
274.Jaipuria, J., et al. Adjuvant radiation compares favorably to chemotherapy in patients with carcinoma penis and nodal positivity restricted to groin. Urol Oncol, 2020. 38: 641.e9.
https://pubmed.ncbi.nlm.nih.gov/32334927/
275.Johnstone, P.A.S., et al. Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. Eur Urol Focus, 2019. 5: 737.
https://pubmed.ncbi.nlm.nih.gov/30327282/
276.Ager, M., et al. Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU Int, 2021. 128: 451.
https://pubmed.ncbi.nlm.nih.gov/33249744/
277.Tang, D.H., et al. Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urol Oncol, 2017. 35: 605 e17.
https://pubmed.ncbi.nlm.nih.gov/28666722/
278.Yuan, Z., et al. Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy. Rep Pract Oncol Radiother, 2019. 24: 593.
https://pubmed.ncbi.nlm.nih.gov/31719799/
279.Yuan, Z., et al. Radiation therapy in the management of the inguinal region in penile cancer: What’s the evidence? Urol Oncol, 2022. 40: 223.
https://pubmed.ncbi.nlm.nih.gov/32482510/
280.Winters, B.R., et al. Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. Urol Oncol, 2018. 36: 92.e11.
https://pubmed.ncbi.nlm.nih.gov/29174944/
281.Choo, R., et al. Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis? Minerva Urol Nefrol, 2020. 72: 474.
https://pubmed.ncbi.nlm.nih.gov/31353875/
282.Maibom, S.L., et al. DaPeCa-4: outcome in penile cancer patients with N3 disease due to extra nodal extension treated with surgery and chemo-irradiation. Scand J Urol, 2020. 54: 334.
https://pubmed.ncbi.nlm.nih.gov/32734838/
283.Haas, G.P., et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol, 1999. 161: 1823.
https://pubmed.ncbi.nlm.nih.gov/10332445/
284.Di Lorenzo, G., et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int, 2012. 110: E661.
https://pubmed.ncbi.nlm.nih.gov/22958571/
285.Zhang, S., et al. Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget, 2015. 6: 32212.
https://pubmed.ncbi.nlm.nih.gov/26311739/
286.Di Lorenzo, G., et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol, 2011. 60: 1280.
https://pubmed.ncbi.nlm.nih.gov/21871710/
287.Liu, W.K., et al. Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre. J Clin Urol, 2021.
https://journals.sagepub.com/doi/full/10.1177/20514158211025913
288.Wang, J., et al. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology, 2015. 85: 1104.
https://pubmed.ncbi.nlm.nih.gov/25819619/
289.Noronha, V., et al. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann, 2012. 4: 150.
https://pubmed.ncbi.nlm.nih.gov/23248520/
290.Bermejo, C., et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol, 2007. 177: 1335.
https://pubmed.ncbi.nlm.nih.gov/17382727/
291.Joshi, V.B., et al. Immune-based therapies in penile cancer. Nat Rev Urol, 2022. 19: 457.
https://pubmed.ncbi.nlm.nih.gov/35851333/
292.Pouessel, D., et al. 715P: Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program. Ann Oncol, 2021. 32: S720.
https://www.annalsofoncology.org/article/S0923-7534(21)02325-5/fulltext
293.Vries, H.M.d., et al. Clinical results of PERICLES: A phase II trial investigating atezolizumab +/- radiotherapy for advanced squamous cell carcinoma of the penis. J Clin Oncol, 2022. 40: 3.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.003
294.Apolo, A.B., et al. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol, 2020. 38: 3672.
https://pubmed.ncbi.nlm.nih.gov/32915679/
295.McGregor, B.A., et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer, 2021. 127: 840.
https://pubmed.ncbi.nlm.nih.gov/33216356/
296.Brown, A., et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology, 2014. 83: 159.
https://pubmed.ncbi.nlm.nih.gov/24238569/
297.Carthon, B.C., et al. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int, 2014. 113: 871.
https://pubmed.ncbi.nlm.nih.gov/24053151/
298.Necchi, A., et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol, 2011. 29: e650.
https://pubmed.ncbi.nlm.nih.gov/21632506/
299.Necchi, A., et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int, 2018. 121: 348.
https://pubmed.ncbi.nlm.nih.gov/28921872/
300.Necchi, A., et al. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. Oncologist, 2022.
https://pubmed.ncbi.nlm.nih.gov/35881043/
301.Lutz, S.T., et al. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol, 2014. 32: 2913.
https://pubmed.ncbi.nlm.nih.gov/25113773/
302.Brennan, J. Adjustment to cancer - coping or personal transition? Psychooncology, 2001. 10: 1.
https://pubmed.ncbi.nlm.nih.gov/11180573/
303.Horenblas, S., et al. Local recurrent tumour after penis-conserving therapy. A plea for long-term follow-up. Br J Urol, 1993. 72: 976.
https://pubmed.ncbi.nlm.nih.gov/8306171/
304.Branney, P., et al. The feasibility of patient reported outcome measures for the care of penile cancer. Int J Urol Nurs, 2022. 16: 138.
https://onlinelibrary.wiley.com/doi/abs/10.1111/ijun.12307
305.Ager, M., et al. MP49-15 - Surveillance CT slgorithm for node positive squamous cell carcinoma of the penis. J Urol, 2019. 201: e711.
https://www.researchgate.net/publication/332608124
306.Arora, A., et al. A0694 - Patterns of recurrence in penile cancer: Implications for surveillance strategies. Eur Urol, 2022. 81: S1033.
https://www.auajournals.org/doi/abs/10.1097/JU.0000000000002622.12
307.Parnham, A.S., et al. Glansectomy and Split-thickness Skin Graft for Penile Cancer. Eur Urol, 2018. 73: 284.
https://pubmed.ncbi.nlm.nih.gov/27746062/
308.Djajadiningrat, R.S., et al. Ultrasound examination and fine needle aspiration cytology-useful for followup of the regional nodes in penile cancer? J Urol, 2014. 191: 652.
https://pubmed.ncbi.nlm.nih.gov/23994372/
309.Branney, P., et al. Mortality and sexuality after diagnosis of penile cancer: a participative study. Int
J Urol Nurs, 2016. 10: 137.
https://onlinelibrary.wiley.com/doi/abs/10.1111/ijun.12106
310.Simpson, W.G., et al. Analysis of Suicide Risk in Patients with Penile Cancer and Review of the Literature. Clin Genitourin Cancer, 2018. 16: e257.
https://pubmed.ncbi.nlm.nih.gov/29126815/
311.Keeley, V., et al. A quality of life measure for limb lymphoedema (LYMQOL). J Lymphoedema, 2010. 5: 26.
https://www.woundsinternational.com/download/wint_article/7140
312.Rosen, R.C., et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 1997. 49: 822.
https://pubmed.ncbi.nlm.nih.gov/9187685/
313.Ware, J.E., et al., Conceptualization and Measurement of Health for Adults in the Health Insurance Study: Vol. I, Model of Health and Methodology. 1980, Santa Monica, CA, USA.
https://www.rand.org/content/dam/rand/pubs/reports/2006/R1987.1.pdf
314.(EORTC), EORTC QLQ-C30 (version 3). 2018. 2022.
https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf
315.Draeger, D.L., et al. Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer. Clin Genitourin Cancer, 2018. 16: e1215.
https://pubmed.ncbi.nlm.nih.gov/30201215/
316.Zigmond, A.S., et al. The hospital anxiety and depression scale. Acta Psychiatr Scand, 1983. 67: 361.
https://pubmed.ncbi.nlm.nih.gov/6880820/
317.Bigelow, D.A., et al. Quality of life of community mental health program clients: validating a measure. Community Ment Health J, 1991. 27: 43.
https://pubmed.ncbi.nlm.nih.gov/2019098/
318.Herbenick, D., et al. The development and validation of the Male Genital Self-Image Scale: results from a nationally representative probability sample of men in the United States. J Sex Med, 2013. 10: 1516.
https://pubmed.ncbi.nlm.nih.gov/23551571/
319.Romero, F.R., et al. Sexual function after partial penectomy for penile cancer. Urology, 2005. 66: 1292.
https://pubmed.ncbi.nlm.nih.gov/16360459/
320.D’Ancona, C.A., et al. Quality of life after partial penectomy for penile carcinoma. Urology, 1997.
50: 593.
https://pubmed.ncbi.nlm.nih.gov/9338738/
321.Kieffer, J.M., et al. Quality of life for patients treated for penile cancer. J Urol, 2014. 192: 1105.
https://pubmed.ncbi.nlm.nih.gov/24747092/
322.Ficarra, V., et al. General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urol Int, 2000. 65: 130.
https://pubmed.ncbi.nlm.nih.gov/11054029/
323.Sosnowski, R., et al. Assessment of quality of life in patients surgically treated for penile cancer: Impact of aggressiveness in surgery. Eur J Oncol Nurs, 2017. 31: 1.
https://pubmed.ncbi.nlm.nih.gov/29173821/
324.Wan, X., et al. A Comparative study of two types of organ-sparing surgeries for early stage penile cancer: Wide local excision vs partial penectomy. Eur J Surg Oncol, 2018. 44: 1425.
https://pubmed.ncbi.nlm.nih.gov/29656798/
325.Skeppner, E., et al. Treatment-seeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma. Eur Urol, 2008. 54: 631.
https://pubmed.ncbi.nlm.nih.gov/18788122/
326.Croghan, S.M., et al. Phallus Preservation in Penile Cancer Surgery: Patient-reported Aesthetic & Functional Outcomes. Urology, 2021. 152: 60.
https://pubmed.ncbi.nlm.nih.gov/33600836/
327.Opjordsmoen, S., et al. Quality of life in patients treated for penile cancer. A follow-up study. Br
J Urol, 1994. 74: 652.
https://pubmed.ncbi.nlm.nih.gov/7827818/
328.Gulino, G., et al. Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma. Indian J Urol, 2013. 29: 119.
https://pubmed.ncbi.nlm.nih.gov/23956513/
329.Carver, B.S., et al. Squamous cell carcinoma of the penis: a retrospective review of forty-five patients in northwest Louisiana. South Med J, 2002. 95: 822.
https://pubmed.ncbi.nlm.nih.gov/12190215/
330.Lukowiak, T.M., et al. Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol, 2021. 84: 1030.
https://pubmed.ncbi.nlm.nih.gov/33279645/
331.Sansalone, S., et al. Sexual outcomes after partial penectomy for penile cancer: results from a multi-institutional study. Asian J Androl, 2017. 19: 57.
https://pubmed.ncbi.nlm.nih.gov/26643562/
332.Sosnowski, R., et al. Assessment of selected quality of life domains in patients who have undergone conservative or radical surgical treatment for penile cancer: an observational study. Sex Health, 2019. 16: 32.
https://pubmed.ncbi.nlm.nih.gov/30532994/
333.Sedigh, O., et al. Sexual function after surgical treatment for penile cancer: Which organ-sparing approach gives the best results? Can Urol Assoc J, 2015. 9: E423.
https://pubmed.ncbi.nlm.nih.gov/26279710/
334.Yang, J., et al. Glans-reconstruction with preputial flap is superior to primary closure for post-surgical restoration of male sexual function in glans-preserving surgery. Andrology, 2014. 2: 729.
https://pubmed.ncbi.nlm.nih.gov/24923484/
335.Morelli, G., et al. Glansectomy with split-thickness skin graft for the treatment of penile carcinoma. Int J Impot Res, 2009. 21: 311.
https://pubmed.ncbi.nlm.nih.gov/19458620/
336.O’Kane, H.F., et al. Outcome of glansectomy and skin grafting in the management of penile cancer. Adv Urol, 2011. 2011: 240824.
https://pubmed.ncbi.nlm.nih.gov/21603193/
337.Palminteri, E., et al. Aesthetic neo-glans reconstruction after penis-sparing surgery for benign, premalignant or malignant penile lesions. Arab J Urol, 2011. 9: 115.
https://pubmed.ncbi.nlm.nih.gov/26579279/
338.Li, J., et al. Organ-sparing surgery for penile cancer: complications and outcomes. Urology, 2011. 78: 1121.
https://pubmed.ncbi.nlm.nih.gov/22054385/
339.Preto, M., et al. Functional and Patient Reported Outcomes Following Total Glans Resurfacing.
J Sex Med, 2021. 18: 1099.
https://pubmed.ncbi.nlm.nih.gov/33935017/
340.Monteiro, L.L., et al. Erectile function after partial penectomy for penile cancer. Int Braz J Urol, 2021. 47: 515.
https://pubmed.ncbi.nlm.nih.gov/33620995/
341.Crook, J.M., et al. Penile brachytherapy: results for 49 patients. Int J Radiat Oncol Biol Phys, 2005. 62: 460.
https://pubmed.ncbi.nlm.nih.gov/15890588/
342.Makarewicz, R., et al. Interstitial brachytherapy for penile cancer: the experience of Oncology Centre in Bydgoszcz. J Contemp Brachyther, 2010. 2: 157.
https://pubmed.ncbi.nlm.nih.gov/27853477/
343.Windahl, T., et al. Sexual function and satisfaction in men after laser treatment for penile carcinoma. J Urol, 2004. 172: 648.
https://pubmed.ncbi.nlm.nih.gov/15247753/
344.Yan, S., et al. Impact of lymphoedema on quality of life following radical lymph node dissection for penile cancer. J. Clin Urol, 2017. 10: 34.
https://www.researchgate.net/publication/310833025
345.Correa, A.F., et al. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 2018.
199: 1238.
https://pubmed.ncbi.nlm.nih.gov/29248557/
346.British Lymphology Society and The Lymphoedema Support Network, Guidelines on the Management of Cellulitis in Lymphoedema 2022. Access date January 2023.
https://www.lymphoedema.org/wp-content/uploads/2022/10/management_cellulitis.pdf
347.Scaglioni, M.F., et al. Systematic review of lymphovenous anastomosis (LVA) for the treatment of lymphedema. Microsurgery, 2017. 37: 947.
https://pubmed.ncbi.nlm.nih.gov/28972280/
348.Jakobsen, J.K., et al. Centralization and Equitable Care in Rare Urogenital Malignancies: The Case for Penile Cancer. Eur Urol Focus, 2021. 7: 924.
https://pubmed.ncbi.nlm.nih.gov/34593356/
349.Jakobsen, J.K., et al. DaPeCa-2: Implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process--A comparative before-and-after study in a tertiary referral centre in Denmark. Scand J Urol, 2016. 50: 80.
https://pubmed.ncbi.nlm.nih.gov/26271679/
350.Ayres, B.E., et al. 50 Has centralisation of penile cancer services in the United Kingdom improved survival? Eur Urol Suppl, 2014. 13: e50.
https://www.sciencedirect.com/science/article/abs/pii/S156990561460052X?via%3Dihub